Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-5288 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-5288 | EXPERIMENTAL | Participants will be administered ALN-5288 in the Double-blind (DB) Period and Open-Label Extension (OLE) Period. |
| Placebo + ALN-5288 | PLACEBO_COMPARATOR | Participants will be administered placebo in the DB Period and ALN-5288 in the OLE Period. |
| Name | Type | Description |
|---|---|---|
| ALN-5288 | DRUG | ALN-5288 will be administered IT. |
| Placebo | DRUG | Placebo will be administered IT. |
Inclusion Criteria: * Is able and willing to meet all study requirements in the opinion of the Investigator * Has a diagnosis of Alzheimer's disease (AD) based on clinical findings supported by cerebrospinal fluid (CSF) biomarkers or positive positron emission tomography (PET) amyloid imaging withi...
Top 20 of 24 competitors
ALN-5288 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with Alzheimer's Disease to evaluate its safety and efficacy.
ALN-5288 targets MAPT, a protein involved in the pathology of Alzheimer's Disease. By targeting MAPT, the drug aims to address a key component of the disease process. This mechanism is being investigated in early-stage clinical trials to determine its potential therapeutic benefit.
ALN-5288 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company. Alnylam is conducting clinical research on this investigational drug for Alzheimer's Disease. The company is listed on the stock exchange under the ticker symbol ALNY.
ALN-5288 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies. The Phase 1 trial is currently recruiting participants to evaluate the drug's safety, tolerability, and pharmacokinetics in patients with Alzheimer's Disease.
ALN-5288 is being evaluated in a Phase 1 clinical trial registered as NCT07214727. This randomized, double-blind, placebo-controlled study is recruiting 50 participants with Alzheimer's Disease across Canada, Netherlands, Spain, and the United Kingdom. The trial is currently active and enrolling patients aged 40 years and older.
ALN-5288 is a distinct investigational compound developed by Alnylam Pharmaceuticals. It is not known to be marketed under any other name. The drug is being studied specifically for its potential role in treating Alzheimer's Disease and is currently in early-stage clinical trials.